Psoriatic Arthritis
📧 Sign up to get email alerts when something new happens for Psoriatic Arthritis.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS research · 2020-11-05Clinical Trial Update: A Study Evaluating the Efficacy and Safety of Guselkumab Administered Subcutaneously in Participants With Active Psoriatic Arthritis [Phase 3]
A Phase 3 trial evaluating the efficacy and safety of subcutaneous guselkumab in participants with active psoriatic arthritis has completed …
-
CLINICAL_TRIALS trial_result · 2020-10-14Clinical Trial Update: Efficacy and Safety Study of Guselkumab in the Treatment of Participants With Active Psoriatic Arthritis (PsA) [Phase 2]
Phase 2 study evaluating the efficacy and safety of guselkumab in active psoriatic arthritis has completed with results posted.
-
CLINICAL_TRIALS trial_result · 2020-10-14Clinical Trial Update: A Study Evaluating the Efficacy and Safety of Guselkumab Administered Subcutaneously in Participants With Active Psoriatic Arthritis Including Those Previously Treated With Biologic Anti -Tumor Necrosis Factor (TNF) Alpha Agent(s) [Phase 3]
Phase 3 trial evaluating guselkumab subcutaneously in active psoriatic arthritis, including prior TNF inhibitors; study completed with resul…
-
CLINICAL_TRIALS trial_result · 2020-10-05Clinical Trial Update: Efficacy of Golimumab in Combination With Methotrexate (MTX) Versus MTX Monotherapy, in Improving Dactylitis, in MTX naïve Psoriatic Arthritis Patients [Phase 3]
Phase 3 trial comparing golimumab plus methotrexate to methotrexate alone in MTX-naïve psoriatic arthritis; study completed with results pos…
-
CLINICAL_TRIALS trial_result · 2020-08-27Clinical Trial Update: AMG 827 in Subjects With Psoriatic Arthritis [Phase 2]
Phase 2 trial of AMG 827 in psoriatic arthritis was terminated; results posted.
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS trial_result · 2020-08-24Clinical Trial Update: Study of the Efficacy and Safety of Secukinumab in Participants With Active Psoriatic Arthritis With Axial Skeleton Involvement [Phase 3]
Phase 3 trial assessing efficacy and safety of secukinumab in active psoriatic arthritis with axial skeleton involvement has completed with …
-
CLINICAL_TRIALS trial_result · 2020-08-20Clinical Trial Update: Study of Efficacy and Safety of Brodalumab in Subjects With Psoriatic Arthritis [Phase 3]
Phase 3 clinical trial evaluating the efficacy and safety of brodalumab in psoriatic arthritis has completed with results posted.
-
CLINICAL_TRIALS trial_result · 2020-08-17Clinical Trial Update: Danish Population-based Assessment of Psoriasis and Psoriatic Arthritis (DANPAPP) [Phase 4]
Phase 4 clinical trial update for a Danish population-based assessment addressing psoriasis and psoriatic arthritis.
-
FDA approval · 2020-07-06FDA Approved: HULIO — Original Application (Biocon Biologics Inc)
FDA approved HULIO (adalimumab-fkjp) from Biocon Biologics Inc via an original Biologics License Application, a biosimilar to adalimumab. Th…
-
FDA approval · 2020-06-16FDA Approved: COSENTYX — Supplemental Application (Novartis Pharmaceuticals Corporation)
The FDA approved a supplemental application for Cosentyx (secukinumab) submitted by Novartis Pharmaceuticals Corporation.
-
CLINICAL_TRIALS trial_result · 2020-06-09Clinical Trial Update: The Effect of n-3 Polyunsaturated Fatty Acids in Patients With Psoriatic Arthritis [NA]
A completed clinical trial investigated the effects of n-3 polyunsaturated fatty acids in patients with psoriatic arthritis, with results po…
-
FDA approval · 2020-05-29FDA Approved: TALTZ — Supplemental Application (Eli Lilly and Company)
FDA approved a supplemental application for TALTZ (ixekizumab) by Eli Lilly and Company. This action pertains to a supplemental filing under…
-
CLINICAL_TRIALS trial_result · 2020-05-21Clinical Trial Update: Open-Label Extension Study Of Tofacitinib In Psoriatic Arthritis [Phase 3]
Open-label extension study of tofacitinib in psoriatic arthritis has completed, with results posted.
-
CLINICAL_TRIALS trial_result · 2020-05-13Clinical Trial Update: Efficacy at 24 Weeks With Long Term Safety, Tolerability and Efficacy up to 5 Years of Secukinumab in Patients of Active Psoriatic Arthritis [Phase 3]
Phase 3 trial update on secukinumab in active psoriatic arthritis showing efficacy at 24 weeks with long-term safety, tolerability, and effi…
-
CLINICAL_TRIALS trial_result · 2020-04-09Clinical Trial Update: Effect of Secukinumab in the Treatment of Psoriatic Arthritis [Phase 2]
Phase 2 clinical trial update evaluating secukinumab for psoriatic arthritis has completed.
-
FDA approval · 2020-03-26FDA Approved: TALTZ — Supplemental Application (Eli Lilly and Company)
The FDA approved a supplemental application for TALTZ (ixekizumab) from Eli Lilly and Company, indicating an updated or expanded indication …
-
CLINICAL_TRIALS trial_result · 2020-03-20Clinical Trial Update: Efficacy and Safety Study of Two Doses of Apremilast (CC-10004) In Japanese Patients With Moderate-To-Severe Plaque-Type Psoriasis [Phase 2]
Phase 2 trial evaluating two doses of apremilast (CC-10004) in Japanese patients with moderate-to-severe plaque-type psoriasis; study comple…
-
EMA withdrawal · 2020-02-20EMA Lapsed: Lifmior (etanercept) — Pfizer Europe MA EEIG
The European Medicines Agency indicates Lifmior (etanercept) has lapsed; the product is no longer active in the market for its indicated con…
-
FDA approval · 2020-02-04FDA Approved: LEFLUNOMIDE — Original Application (Lupin Pharmaceuticals, Inc.)
FDA approved the original application for Leflunomide from Lupin Pharmaceuticals, establishing a generic version of the drug.
-
CLINICAL_TRIALS trial_result · 2020-01-13Clinical Trial Update: Post-Marketing Use Of CT-P13 (Infliximab) For Standard Of Care Treatment Of Rheumatoid Diseases Who Are Naïve To Biologics Or Switched From Remicade
A completed clinical trial evaluating post-marketing use of CT-P13 (infliximab) for standard care in patients with rheumatoid diseases who a…
-
CLINICAL_TRIALS trial_result · 2020-01-02Clinical Trial Update: T Cells and TNF (Tumor Necrosis Factor): The Impact of TNF Blockade
Clinical trial update on T cells and TNF blockade in inflammatory diseases; study completed with results posted.
-
FDA label_change · 2019-12-26FDA Approved: OTREXUP — Supplemental Application (Antares Pharma, Inc.)
FDA approved a supplemental application for OTREXUP (methotrexate) from Antares Pharma, Inc., leading to changes in the labeling for this su…
-
FDA approval · 2019-12-12FDA Approved: XELJANZ XR — Supplemental Application (Pfizer Laboratories Div Pfizer Inc)
FDA approved a supplemental application for XELJANZ XR (tofacitinib) from Pfizer Laboratories Div Pfizer Inc, indicating an update to the pr…
-
CLINICAL_TRIALS trial_result · 2019-12-09Clinical Trial Update: A Phase 4 Clinical Study of Brodalumab [Phase 4]
A Phase 4 clinical study of brodalumab completed, investigating psoriasis vulgaris and psoriatic arthritis (with related pustular and erythr…
-
FDA approval · 2019-12-06FDA Approved: AVSOLA — Original Application (Amgen, Inc)
FDA approved AVSOLA (infliximab-axxq) from Amgen as a biosimilar to infliximab, for the same indications as the reference product.